Thermal dosimetry for bladder hyperthermia treatment. An overview.

The urinary bladder is a fluid-filled organ. This makes, on the one hand, the internal surface of the bladder wall relatively easy to heat and ensures in most cases a relatively homogeneous temperature distribution; on the other hand the variable volume, organ motion, and moving fluid cause artefacts for most non-invasive thermometry methods, and require additional efforts in planning accurate thermal treatment of bladder cancer. We give an overview of the thermometry methods currently used and investigated for hyperthermia treatments of bladder cancer, and discuss their advantages and disadvantages within the context of the specific disease (muscle-invasive or non-muscle-invasive bladder cancer) and the heating technique used. The role of treatment simulation to determine the thermal dose delivered is also discussed. Generally speaking, invasive measurement methods are more accurate than non-invasive methods, but provide more limited spatial information; therefore, a combination of both is desirable, preferably supplemented by simulations. Current efforts at research and clinical centres continue to improve non-invasive thermometry methods and the reliability of treatment planning and control software. Due to the challenges in measuring temperature across the non-stationary bladder wall and surrounding tissues, more research is needed to increase our knowledge about the penetration depth and typical heating pattern of the various hyperthermia devices, in order to further improve treatments. The ability to better determine the delivered thermal dose will enable clinicians to investigate the optimal treatment parameters, and consequentially, to give better controlled, thus even more reliable and effective, thermal treatments

4D cone-beam CT imaging for guidance in radiation therapy: Setup verification by use of implanted fiducial markers

The use of 4D cone-beam computed tomography (CBCT) and fiducial markers for guidance during radiation therapy of mobile tumors is challenging due to the trade-off between image quality, imaging dose, and scanning time. We aimed to investigate the visibility of markers and the feasibility of marker-based 4D registration and manual respiration-induced marker motion quantification for different CBCT acquisition settings. A dynamic thorax phantom and a patient with implanted gold markers were included. For both the phantom and patient, the peak-to-peak amplitude of marker motion in the cranial-caudal direction ranged from 5.3 to 14.0 mm, which did not affect the marker visibility and the associated marker-based registration feasibility. While using a medium field of view (FOV) and the same total imaging dose as is applied for 3D CBCT scanning in our clinic, it was feasible to attain an improved marker visibility by reducing the imaging dose per projection and increasing the number of projection images. For a small FOV with a shorter rotation arc but similar total imaging dose, streak artifacts were reduced due to using a smaller sampling angle. Additionally, the use of a small FOV allowed reducing total imaging dose and scanning time (∼2.5 min) without losing the marker visibility. In conclusion, by using 4D CBCT with identical or lower imaging dose and a reduced gantry speed, it is feasible to attain sufficient marker visibility for marker-based 4D setup verification. Moreover, regardless of the settings, manual marker motion quantification can achieve a high accuracy with the error <1.2 mm

Short-Course External Beam Radiotherapy Versus Brachytherapy for Palliation of Dysphagia in Esophageal Cancer: A Matched Comparison of Two Prospective Trials

Contains fulltext : 221576.pdf (Publisher’s version ) (Open Access

Immediate treatment vs. active-surveillance in very-low-risk prostate cancer: the role of patient-, tumour-, and hospital-related factors

Item does not contain fulltex